Human pathology
-
Columnar cell lesions of the breast are a spectrum of lesions in the terminal duct lobular units, which include columnar cell change, columnar cell hyperplasia, and columnar cell change or columnar cell hyperplasia with atypia. The latter was designated by the World Health Organization as flat epithelial atypia. We studied a group of pathology trainees (pathology residents and fellows) as a model for the impact of a training tutorial on the ability to distinguish various types of columnar cell lesions. ⋯ The agreements on columnar cell lesions, columnar cell hyperplasia, and flat epithelial atypia after the tutorial were significantly better than those before the tutorial. No significant difference in agreement was observed on columnar cell change before and after the tutorial, but the kappa value improved. We conclude that appropriate tutorial training of diagnostic criteria can increase diagnostic agreement on columnar cell lesions among pathology residents, fellows, and presumably general pathologists in practice.
-
Up to 30% of pheochromocytomas and paragangliomas are associated with germline RET, Von Hippel-Lindau (VHL), neurofibromatosis type I (NF1), and succinate dehydrogenase subunits (SDHB, SDHC, and SDHD) mutations. Genetic testing allows familial counseling and identifies subjects at high risk of malignancy (SDHB mutations) or significant multiorgan disease (RET, VHL, or NF1). However, conventional genetic testing for all loci is burdensome and costly. ⋯ We also performed immunohistochemistry for SDHB on 143 consecutive unselected tumors of which 21 were weak diffuse or negative. As SDH mutations are virtually always germline, we conclude that approximately 15% of all pheochromocytomas or paragangliomas are associated with germline SDH mutation and that immunohistochemistry can be used to triage genetic testing. Completely absent staining is more commonly found with SDHB mutation, whereas weak diffuse staining often occurs with SDHD mutation.
-
Intraductal papillary mucinous neoplasms of the pancreas are subclassified based on morphological features, and different immunohistochemical profiles have been identified in association with the subtypes. We previously reported that S100P was an early developmental marker of pancreatic carcinogenesis and that there was higher S100P expression in intraductal papillary mucinous neoplasms than in normal pancreatic ductal epithelium. However, there have been no reports on novel diagnostic markers to distinguish intraductal papillary mucinous neoplasm from nonneoplastic lesions. ⋯ Furthermore, S100P was clearly expressed in the invasive component of intraductal papillary mucinous neoplasms (32/32; 100%), including perineural and lymphatic and minimal invasion. On the other hand, MUC5AC was expressed in only 23 cases of 32 invasive components (P < .01). These data suggest that the S100P antibody may be a useful marker for detecting all types of intraductal papillary mucinous neoplasms.